Can targeting molecular interactions be a therapeutic strategy?
Yes, targeting specific molecular interactions has become a cornerstone of modern cancer therapy. For instance, tyrosine kinase inhibitors target aberrant kinase activity in cancer cells, while immune checkpoint inhibitors disrupt inhibitory interactions between cancer cells and immune cells, enhancing anti-tumor immunity.
